We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Jordanian drugmaker Hikma Pharmaceuticals will sell off two drugs and relinquish marketing rights to a third to avoid tangling with the Federal Trade Commission on its planned purchase of a Boehringer Ingelheim subsidiary. Read More
The FDA sent PTC Therapeutics a refusal to file letter for Translarna, its candidate for the treatment of nonsense mutation Duchenne muscular dystrophy. Read More
Regular price reevaluations can lower drug prices in individual European countries, but the only way to ensure significant price cuts is through EU-wide collaboration, according to a new report. Read More
After years of uncontrolled spending, the UK’s troubled Cancer Drugs Fund has presented the National Health Service with a restructuring plan to get back on track. Read More
Six new drugs scored wins at the European Medicines Agency, scooping up recommendations for marketing authorization from the Committee for Medicinal Products for Human Use. Read More
Romozosumab met its primary endpoint by minimizing new vertebral fractures in postmenopausal women with osteoporosis through months 12 and 24. Read More